Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on December 1, 2022, covering events occurring on December 2, 2022. The filing primarily addresses the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation terms rather than financial performance.
Material Changes
The material change reported is the appointment of Steve Sabus as Chief Commercial Officer, effective December 5, 2022. Mr. Sabus joins from Turning Point Therapeutics, where he served as Chief Commercial Officer until its acquisition by Bristol-Myers Squibb in August 2022. Prior to that, he spent 15 years at Astellas Pharma.
Guidance, Outlook, and Compensation Details
The filing details the terms of the Employment Agreement entered into on December 1, 2022:
- Base Salary: $495,000 annually.
- Target Bonus: 40% of base salary.
- Equity Grant: One-time option to purchase 220,000 shares of common stock. The exercise price is the closing price on December 5, 2022.
- Vesting Schedule: 25% vests on the one-year anniversary of the commencement date; the remaining 75% vests monthly over the subsequent 36 months.
- Severance Provisions:
- Termination without cause/Good reason: 9 months base salary, 9 months health benefits, and accelerated vesting of equity that would have vested within 12 months.
- Change in Control (within 3 months prior or 12 months after): 12 months base salary plus 100% of the greater of the average annual target bonus or current target bonus, 12 months health benefits, and full accelerated vesting of all unvested options.
The filing states there are no family relationships between Mr. Sabus and existing directors or officers, and no related party transactions exist.
Investor Verification Checklist
- Verify the closing stock price on December 5, 2022, to determine the exercise price of the 220,000 share option grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Assess the impact of the new Chief Commercial Officer's experience on the company's commercialization strategy for its drug candidates.
- Confirm the total potential cash and equity liability associated with the severance provisions in the event of a change in control.